Loading
HLX26 is an experimental monoclonal antibody from Shanghai Henlius Biotech in phase 2 trials for non-small-cell lung cancer, aimed at LAG-3.
HLX26 is a monoclonal antibody developed by Shanghai Henlius Biotech. Its target is LAG-3 (the sponsor names LAG-3). The sponsor states: An anti-LAG-3 monoclonal antibody injection that blocks LAG-3 signalling to enhance T-cell mediated anti-tumour immunity, studied in combination with PD-1 inhibition and chemotherapy. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT05787613, plans to enrol 132 participants with primary completion was scheduled for 2026-02 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
An anti-LAG-3 monoclonal antibody injection that blocks LAG-3 signalling to enhance T-cell mediated anti-tumour immunity, studied in combination with PD-1 inhibition and chemotherapy. Connects to LAG-3.
1.HLX26 binds LAG-3.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HLX26" OR ABSTRACT:"HLX26" OR TITLE:"Anti-LAG-3 monoclonal Antibody Injection" OR ABSTRACT:"Anti-LAG-3 monoclonal Antibody Injection") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HLX26, not a curated reading list.
Shares Shanghai Henlius Biotech, Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.